文章：

HER2-0与HER2低表达乳腺癌患者的临床特征及预后分析：基于新辅助化疗患者的真实世界数据

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy

原文发布日期：22 September 2023

DOI: 10.3390/cancers15194678

类型: Article

开放获取: 是

英文摘要：

In our study, we observed the long-term survival outcomes investigated for HER2-0 and HER2-low-positive breast cancer patients who received neoadjuvant chemotherapy. Between 1998 and 2020, 10,333 patients with primary breast cancer were treated, including 1373 patients with HER2-0 or HER2-low-positive disease with neoadjuvant chemotherapy. Descriptive analyses were performed, and logistic regression models and survival analyses were calculated for disease-free survival (DFS) and overall survival (OS). Among the 1373 patients, 930 (67.73%) had HER2-low-positive and 443 (32.27%) had HER2-0 tumors. Patients with HER2-0 tumors had a significantly better pathological complete response, 29.25% vs. 20.09%, and pathological complete response/in situ, 31.97% vs. 24.08%, than patients with HER2-low-positive tumors (p< 0.001;p= 0.003), regardless of the hormone receptor (HR) status. No statistically significant differences were observed for the HR-positive (p= 0.315;p= 0.43) or HR-negative subgroups (p= 0.573;p= 0.931). DFS and OS were significantly longer for HR-positive, HER2-low-positive patients (log-rankp= 0.02;p= 0.012). OS was significantly longer for HR-negative, HER2-0 patients (log-rankp= 0.032). No significant DFS differences were found for the HR-negative cohort (log-rankp= 0.232). For the overall cohort, no significant differences were noted between HER2-low-positive and HER2-0 patients, either for DFS (log-rankp= 0.220) or OS (log-rankp= 0.403). These results show different survival outcomes for HER2-0 and HER2-low-positive tumors relative to HR status. These different cohorts can be identified using standardized immunohistochemistry, even retrospectively.

摘要翻译： 

本研究观察了接受新辅助化疗的HER2-0与HER2低表达乳腺癌患者的长期生存结局。1998年至2020年间共治疗10,333例原发性乳腺癌患者，其中包含1,373例接受新辅助化疗的HER2-0或HER2低表达患者。研究进行了描述性分析，并采用逻辑回归模型和生存分析法计算无病生存期（DFS）与总生存期（OS）。在1,373例患者中，HER2低表达型930例（67.73%），HER2-0型443例（32.27%）。无论激素受体（HR）状态如何，HER2-0型患者均显示出显著更优的病理完全缓解率（29.25% vs. 20.09%）及病理完全缓解/原位癌缓解率（31.97% vs. 24.08%）（p<0.001；p=0.003）。在HR阳性亚组（p=0.315；p=0.43）或HR阴性亚组（p=0.573；p=0.931）中未观察到统计学显著差异。HR阳性/HER2低表达患者的DFS与OS显著延长（时序检验p=0.02；p=0.012），而HR阴性/HER2-0患者的OS显著延长（时序检验p=0.032）。HR阴性队列的DFS未见显著差异（时序检验p=0.232）。在整个队列中，HER2低表达与HER2-0患者在DFS（时序检验p=0.220）和OS（时序检验p=0.403）方面均无显著差异。这些结果表明，HER2-0与HER2低表达肿瘤的生存结局因HR状态而异。通过标准化免疫组化检测可识别这些不同亚群，甚至可进行回顾性分析。

原文链接：

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy